Healthcare Industry News: Impella
News Release - March 5, 2009
Abiomed Appoints Michael Howley as Vice President and General Manager of Global Sales and Marketing
DANVERS, Mass.--(HSMN NewsFeed)--Abiomed, Inc. (NASDAQ: ABMD ), a leading provider of heart recovery products designed to recover hearts and eliminate in-hospital deaths from heart attacks and high risk percutaneous coronary interventions (PCI), announced today the appointment of Michael Howley as Vice President and General Manager, Global Sales and Marketing. Mr. Howley brings more than 20 years of healthcare sales and marketing management experience, as well as a highly successful background in commercial sales achievements at General Electric Healthcare, with expertise in leading varying sizes of healthcare businesses ranging from X-ray imaging, PET/CT, ultrasound, Lunar bone densitometers to clinical information software systems.“We are extremely pleased to welcome Mike to the management team. He has a proven track record of success across several healthcare technology markets and has been formally recognized and commended for his superior leadership in nearly every position he has held,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. “An experienced senior executive, Mike has demonstrated his ability to grow revenue, gross margin, and market share, while adapting to different distribution models and technologies. He will be a highly capable contributor to the further adoption and utilization of our heart recovery technologies.”
Prior to joining Abiomed, Mr. Howley spent 20 years at GE Healthcare. From 2006 to 2009, he was General Manager at GE Healthcare, overseeing the Americas X-ray and Interventional Radiology division, with revenues over $400 million. In this role, Mr. Howley developed strategic marketing campaigns directed to drive sales and X-ray portfolio adoption. In this role, Mr. Howley led the business to grow revenues and gain significant market share each year.
Mr. Howley also held the General Manager position for the Clinical Information Systems at GE, a $200 million healthcare software division, where he drove the business strategy, messaging and strategic vision. Previously, he was the Americas Sales Manager of Functional and Molecular Imaging, where he led a hybrid model of sales specialists, a paradigm that was new to GE. In this role, Mr. Howley helped achieve order growth by 30 percent for a new imaging platform, which translated into a significant increase in market share and gross margin. Prior to this role, Mr. Howley held several other national and regional sales positions at GE, beginning his tenure with the company in 1989.
Mr. Howley received a bachelor’s degree in business administration and marketing from Auburn University.
“I am thrilled to join the leadership team at Abiomed as we expand the presence of Impella in the catherization lab,” said Mr. Howley. “The Company is experiencing rapid growth and I am looking forward to implementing a sales strategy focused on establishing new customer accounts while driving utilization.”
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
Source: Abiomed
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
